Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Moodys
Merck
Express Scripts
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Litigation Details for Pharmacia & Upjohn v. Sicor Inc. (D. Del. 2004)

See Plans and Pricing

« Back to Dashboard

Pharmacia & Upjohn v. Sicor Inc. (D. Del. 2004)

Docket   Start Trial Date Filed 2004-07-08
Court District Court, D. Delaware Date Terminated 2006-11-21
Cause 35:271 Patent Infringement Assigned To Kent A. Jordan
Jury Demand Defendant Referred To
Parties PHARMACIA & UPJOHN COMPANY; SICOR INC.; SICOR PHARMACEUTICALS INC.
Patents 4,001,323; 4,310,515; 4,599,353; 4,619,935; 4,721,723; 5,900,423; 6,080,759; 6,172,233; 8,003,819; 9,555,005
Attorneys John G. Day; Maryellen Noreika; Steven J. Balick; Tiffany Geyer Lydon
Link to Docket External link to docket
Small Molecule Drugs cited in Pharmacia & Upjohn v. Sicor Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Pharmacia & Upjohn v. Sicor Inc. (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2005-09-26 114 Exhibits 1-2 design. Patents which describe potentially useful information include: (a) Us mem No. 4,310,515 Although…Australian letters Patent No. 598,197 ("the Patent"). I have earefully read the Patent. A number of…the same as for the Patent in suit. Austialian Patent No. 572,002 This FCE patent describes a stable, …is, patents disclosing any novel ideas used in formulating anti~cancer compounds), and any patents relating…described inthe Patent. The data listed as Tl etc refer to the data reported in the patent (eg 'l' External link to document
2005-10-05 124 Redacted Document Pharmacv, 1 rhird Edition (Id., 11 3»5);7 U.S. Patent No. 4,310,515 (Id., 11 36); 7 Sicor’s Amended Counterclaim…invalidity of the ‘ 197 patent, a foreign application related to the ‘285 patent (the “Upjohn Letter”);…withholding of material references from the U. S. Patent and Trademark Office (the “PTO”),; and its delayed… which challenged Pharmacia’s arguments for patentability in its ‘742 Application. (See Amended Counterclaim…request to have the PTO reexamine the plaintiffs patent. Remington Arms Co. v. Modern Muzzleloading, Inc External link to document
2005-11-07 157 Exhibit C part 1 of 2 U.S. Patent Application Serial No. 07/827,742. Granatek et al. (1982) U.S. Patent No. 4,310,515. 28 …received a patent in 1971 on doxorubicin (U.S. Patent Number 3,590,028) and another patent in 1974 on …co-inventor of six issued patents Among the topics discussed in these papers and/or patents are enzymatic reaction…lecosides l have reviewed U.S. Patent Number 6,107,285. In general, the ‘285 patent deals with anthracycline… other publications D. The ‘285 Patent ln reading the ‘285 patent it became readily apparent that many External link to document
2006-01-27 195 Exhibit 11 infringement of U.S. Patent No. 4,721,723 (the " '723 A. Choice of Law Patent"). We refer…the substantive patent law of the U.S. Patent No. 5,900,423 (the " '423 Patent"). On …collectively upon an existing patent because (1) the required patent "TorPharm" or "Defendant…infringement of U.S. Patent No. 6,080,759 disputes and other procedural issues unique to patent (the "…questions that are not of U.S. Patent No. 6,133,944 (the " '944 Patent"). SB filed themselves External link to document
2006-03-17 209 Exhibit B: black-lined version Australian Litigation was U.S. Patent No. 4,310,515. The ‘515 patent was discussed in Dr. Charman’s … Invalidity of the ‘285 Patent The ‘285 patent is invalid under the patent laws of the United States…applied for patent rights to what ultimately became the ‘285 patent, in United States Patent Application…except admits that United States Patent No. 6,107,285 (the “‘285 patent”) was issued on August 22, 2000…Declaratory Relief: The ‘285 Patent is Invalid 7. The ‘285 patent is invalid because it fails External link to document
2006-03-28 212 Amended Answer to Complaint Australian Litigation was U.S. Patent No. 4,310,515. The ‘515 patent was discussed in Dr. Charman’s expert…except admits that United States Patent No. 6,107,285 (the “‘285 patent”) was issued on August 22, 2000…Invalidity of the ‘285 Patcnt The ‘285 patent is invalid under the patent laws of the United States, including…for Declaratorv Reliei`: The ‘285 Patent is Invalid 7. The ‘285 patent is invalid because it fails to comply… of a patent application, all individuals associated with the filing or prosecution of a patent application External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKinsey
Colorcon
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.